Pharmaceuticals

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

Two Bay Area event firms gain a key certification, strategically positioning them to tap into the lucrative healthcare conference market via supplier diversity.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

A routine filing by hedge fund Balyasny Asset Management may have just put Avadel Pharmaceuticals in the M&A spotlight. Here's what the signal means.

A new tech platform is untangling the web of pharmacy sourcing for wellness clinics, promising to slash costs and administrative headaches. Is this the future?

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

Acadia's new powder form of the only Rett syndrome drug offers families vital choice, easing daily care and showing the power of patient-led innovation.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

A shocking 9,000% rise in senior overdose deaths sparks a new video initiative. But is education enough to combat a crisis hidden in plain sight?

Oak Hill Advisors' record fundraise underscores a major shift in corporate finance, as private credit becomes the go-to capital source for large-cap firms.